Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

calicheamicin theta(1)I

Known as: calicheamicin theta1 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Detailed behind-the-scenes accounts of the total syntheses of calicheamicin γ(1)(I), Taxol(®), and brevetoxin A are discussed… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid leukemia (AML). Gemtuzumab ozogamicin (GO), an… Expand
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Gemtuzumab ozogamicin (GO) contains an anti-CD33 antibody to facilitate uptake of a toxic calicheamicin-gamma(1) derivative… Expand
  • figure 1
  • table 1
Is this relevant?
Review
2007
Review
2007
  • Kirsten Dahm
  • Journal of cellular biochemistry
  • 2007
  • Corpus ID: 2381562
Cells, which lacked the activity of the nuclease Artemis, retained approximately 10% of unrepaired double strand breaks (DSBs) at… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Gemtuzumab ozogamicin (GO; Mylotarg), a novel immunoconjugate used for treatment of acute myeloid leukemia (AML), contains the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
Calicheamicin ϑII is a member of the enediyne class of antitumor antibiotics that bind to DNA and induce apoptosis. These… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
It is assumed that the efficient antitumor activity of calicheamicin gamma1 is mediated by its ability to introduce DNA double… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
The anti-CD33 antibody, P67.6, has been chosen to target the potently cytotoxic calicheamicin antitumor antibiotics to acute… Expand
Is this relevant?
2000
2000
In search for a new therapeutic approach for metastasized renal cell carcinoma (RCC), we evaluated the cytotoxicity of a novel… Expand
Is this relevant?
1998
1998
The suppression of metastases in malignant diseases is one of the major goals in targeted chemotherapy. This was achieved with an… Expand
Is this relevant?